MyoKardia, Inc.

Organization Address
333 Allerton Ave
South San Francisco, CA 94080

Organization Phone
(650) 741-0900



Organization Description

MyoKardia’s mission is to revolutionize the treatment of genetic cardiomyopathies and related heart disease through exploiting advances in sarcomere-related biochemistry and molecular biology. MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease. The company’s first programs include hypertrophic and dilated cardiomyopathy, which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade. MyoKardia’s proprietary drug discovery platform brings together advances from the fields of cardiovascular genomics and heart muscle biology to enable its scientists to target certain heart disease ‘at its source.’ This genetically targeted approach has the potential to revolutionize the treatment of cardiomyopathies, and ultimately a broader spectrum of cardiovascular disease, including heart failure.

Clinical Development Stage